Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 52 clinical trials
The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-sch nlein Purpura

The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with Henoch-schnlein purpura.

Accepts healthy volunteers
  • 22 Oct, 2021
  • 1 location
Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency

accounts for 30-50% of all cases. SCID-X1 is caused by defects in the common cytokine receptor gamma chain, which was originally identified as a component of the high affinity interleukin-2 receptor (IL2RG

  • 03 Feb, 2022
  • 1 location
Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia

After complete remission, elderly AML patients cannot tolerate hematopoietic stem cell transplantation and standard-dose consolidation chemotherapy, and the 5-year survival rate is around 10%. Therefore, it is necessary to explore treatment strategy that can support chemotherapy or improve immunity. Umbilical cord blood is rich in hematopoietic stem cells and immune …

  • 01 Sep, 2021
  • 2 locations
Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia

Different types of stem cells have recently been studied in clinical trial on ischemic disease of the heart and muscular arteries. Adipose derived stem cell, have shown in vitro and in vivo models a stronger potential of success in recovering from ischemic disease and oxygenation of the tissues. The investigators …

  • 25 Jan, 2021
  • 2 locations
Saltikva for Metastatic Pancreatic Cancer

Objectives: Assess the efficacy of multiple dose oral administration of Saltikva, an attenuated strain of Salmonella Typhimurium expressing IL-2, in patients with metastatic pancreatic cancer on standard chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane and Saltikva). Study Rationale: The addition of Saltikva to the standard of care regimen for Stage IV metastatic …

  • 13 May, 2022
  • 1 location
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant

The haematological neoplasia relapse is the cause of higher mortality after allogeneic stem cell transplantation (HSCT). When transplantation fails the most common therapeutic strategy is to increase the antitumor activity of the donor's immune system through the infusion of donor Lymphocytes (DLI). The use of DLI may limit the relapse, …

  • 01 Jan, 2022
  • 1 location
Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

This study will be conducted at Children's Healthcare of Atlanta, in Atlanta, Georgia for a total duration of 24 months. The electrical neuromuscular stimulation device used in this study is the VitalStim 400, which has been used in multiple previous clinical studies for modulation of pain and has received FDA …

plasma exchange
immune globulin
  • 11 Mar, 2022
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma

t-cell lymphoma
measurable disease
refractory t-cell non-hodgkin lymphoma
  • 26 Mar, 2022
  • 21 locations
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

The purpose of this study is to determine the safety and recommended Phase 2 dose (RP2D) of JNJ-67856633 and ibrutinib in combination in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part A (Dose Escalation) and to evaluate safety of JNJ-67856633 and ibrutinib in combination, …

chronic lymphocytic leukemia
  • 29 Apr, 2022
  • 11 locations
Low-dose Interleukin-2 in Women With Unexplained Miscarriages

The purpose of this study is to demonstrate the ability of low dose IL-2 to stimulate peripheral blood Tregs of women with unexplained repeated early spontaneous miscarriages for development of a therapy to prevent fetal rejection by low dose IL-2.

  • 16 Mar, 2021
  • 3 locations